EGFR/HER2 inhibitor AEE788 increases ER-mediated transcription in HER2/ER-positive breast cancer cells but functions synergistically with endocrine therapy.
about
mRNA profiling reveals determinants of trastuzumab efficiency in HER2-positive breast cancerEffectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivo.Identification of chemokine receptors as potential modulators of endocrine resistance in oestrogen receptor-positive breast cancers.The combination of methylsulfonylmethane and tamoxifen inhibits the Jak2/STAT5b pathway and synergistically inhibits tumor growth and metastasis in ER-positive breast cancer xenografts.Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance.Blocking the interaction of vascular endothelial growth factor receptors with their ligands and their effector signaling as a novel therapeutic target for cancer: time for a new look?Small molecule tyrosine kinase inhibitors of ErbB2/HER2/Neu in the treatment of aggressive breast cancer.Long-term remission of hormone receptor-positive/HER2-positive metastatic breast cancer due to combined treatment with everolimus/trastuzumab/exemestane: A case report.Overcoming Resistance to Endocrine Therapy in Breast Cancer: New Approaches to a Nagging Problem.Release of HER2 repression of trefoil factor 3 (TFF3) expression mediates trastuzumab resistance in HER2+/ER+ mammary carcinoma.Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer.
P2860
Q28543647-218B599E-3005-4339-B462-2B7920DD0AC1Q33739267-065C1640-729C-4B90-851B-BAB1E3B1039CQ35000307-D2BDD29F-1441-48FD-AD1C-AB42CB6DD702Q35666599-16249C9B-2745-4208-9162-D857604335A4Q36589865-37858F60-26D0-42FD-95E0-3AECE033A2FEQ37921797-4E3B94C6-E158-46A1-B905-8F906C8D8F81Q38253835-C2802A1C-4666-485C-81D6-B1EA7A9C1694Q41142443-A3A94A98-765F-4235-9D54-244BF9C68048Q42755954-5F7202EB-D7CC-4782-9E1A-A5B54BF893D1Q47114555-E5B6D23C-50AF-4E32-BC6A-468A652C534FQ55479657-16DE0F2B-A8F9-4A45-8541-9C51D15A45E3
P2860
EGFR/HER2 inhibitor AEE788 increases ER-mediated transcription in HER2/ER-positive breast cancer cells but functions synergistically with endocrine therapy.
description
2010 nî lūn-bûn
@nan
2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
EGFR/HER2 inhibitor AEE788 inc ...... ically with endocrine therapy.
@ast
EGFR/HER2 inhibitor AEE788 inc ...... ically with endocrine therapy.
@en
type
label
EGFR/HER2 inhibitor AEE788 inc ...... ically with endocrine therapy.
@ast
EGFR/HER2 inhibitor AEE788 inc ...... ically with endocrine therapy.
@en
prefLabel
EGFR/HER2 inhibitor AEE788 inc ...... ically with endocrine therapy.
@ast
EGFR/HER2 inhibitor AEE788 inc ...... ically with endocrine therapy.
@en
P2093
P2860
P356
P1476
EGFR/HER2 inhibitor AEE788 inc ...... ically with endocrine therapy.
@en
P2093
A Thornhill
L-A Martin
S Pancholi
S R Johnston
P2860
P2888
P304
P356
10.1038/SJ.BJC.6605641
P407
P577
2010-04-01T00:00:00Z
P5875
P6179
1039034121